The Early Treatment Phase in Parkinson’s Disease: Not a Honeymoon for All, Not a Honeymoon at All?
Open Access
- 24 February 2023
- journal article
- editorial
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 13 (3) , 323-328
Abstract
The discovery of levodopa in the late 60 s of twentieth century was a ‘golden moment’ for people with Parkinson’s disease (PD). Unfortunately, clinical experience showed that some symptoms escaped from symptomatic control, and long-term complications developed. Back then, neurologists coined the term “honeymoon period” for the early phase of uncomplicated response to levodopa, and it continues to be used in scientific literature. However, medical terms are no longer restricted to professionals, and few people with PD relate to the notion of a “honeymoon”. We examine the reasons why this term, once helpful, but inaccurate and inappropriate, should be abandoned.Keywords
This publication has 26 references indexed in Scilit:
- Traitement médicamenteux de la maladie de Parkinson à la phase précoce (de novo et « lune de miel »)Revue Neurologique, 2014
- A Second Honeymoon for Parkinson's Disease?New England Journal of Medicine, 2013
- Long‐term outcomes of surgical therapies for Parkinson's diseaseMovement Disorders, 2012
- Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 yearsMovement Disorders, 2004
- Limitations of current Parkinson's disease therapyAnnals of Neurology, 2003
- What should we say to patients with symptoms unexplained by disease? The “number needed to offend”BMJ, 2002
- Drugs for Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Psychosocial factors in Parkinson's diseaseBritish Journal of Clinical Psychology, 1989
- LONG-TERM SIDE-EFFECTS OF LEVODOPAThe Lancet, 1971
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969